European award for medicinal chemists: New active ingredients for the treatment of infections

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

Background Research:

Martin Empting is a recognized researcher specializing in medicinal chemistry. His research focuses on creating new substances that can combat bacterial and viral infections – an area of growing concern due to antibiotic resistance and the emergence of new infectious diseases. He has demonstrated exceptional skill and innovation in his field, which is a huge asset in the rapidly evolving discipline of medicinal chemistry.

He was awarded the Young Medicinal Chemist in Academia Prize by the European Federation for Medicinal Chemistry (EFMC). The EFMC is an organization that seeks to advance research and education in the field of medicinal chemistry, linking scientists at universities, industries, research facilities and regulatory agencies all over Europe.

The award recognizes young chemists who are making significant contributions to their academic field. It’s a highly prestigious award given only to those showing great promise early on in their careers.

FAQs

1. Who is Martin Empting?
– Martin Empting is a researcher specializing in medicinal chemistry. His work centers around developing new substances for the treatment of bacterial and viral infections.

2. What award did he win?
– He received runner-up for the Young Medicinal Chemist in Academia Prize by the European Federation for Medicinal Chemistry (EFMC).

3. What exactly does he work on?
– Empting works towards creating active substances (chemical compounds with specific therapeutic effects) that will be used against infectious microbes like bacteria or viruses –agents causing increasingly worrisome public health issues due to resistance to existing medications.

4. Why is this news significant?
– This news highlights how innovative minds like Empting are striving hard through clinical studies towards reaching sustainable solutions against infections.

5.How does this impact us as average people?
– As potential patients who may need treatments against various infections, advancements made by researchers like him make sure we have effective medicines available when needed.

6.What does it mean to be a runner-up for this award?
– As a runner-up, Empting demonstrated great promise in his field. The award acknowledges exceptional chemists who are early in their career and hold potential for significant future contributions.

7.What is the European Federation of Medicinal Chemistry (EFMC)?
– EFMC is a professional organization supporting advancement of knowledge, research, and education in the field of medicinal chemistry across Europe. The federation connects scientists active in various related disciplines based at universities, pharmaceutical businesses, other research institutions and regulatory bodies.

8.What does a medicinal chemist do?
– A medicinal chemist engages in scientific research focused on discovery and development of new therapeutic substances which then can become medicines available to patients.

Originamitteilung:

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Rainforest protection reduces the number of respiratory diseases

Rainforest protection is not only good for biodiversity and the climate – it also noticeably improves the health of humans who live in the corresponding regions. This is the conclusion drawn by a current study by the University of Bonn and the Universidade Federal de Minas Gerais in Brazil. In this, the researchers show that measures to combat slash-and-burn techniques significantly reduce the concentration of particulate matter in the air. The number of hospital stays and deaths due to respiratory diseases thus also decreases. The results have been published now in the journal Nature Communications, Earth & Environment.

Read More

Regenwaldschutz senkt Zahl der Atemwegserkrankungen

Regenwaldschutz ist nicht nur gut für Biodiversität und Klima – auch die Gesundheit der Menschen, die in den entsprechenden Gebieten leben, verbessert sich dadurch spürbar. Zu diesem Schluss kommt eine aktuelle Studie der Universität Bonn und der Universidade Federal de Minas Gerais in Brasilien. Die Forscher zeigen darin, dass Maßnahmen gegen Brandrodung die Feinstaub-Konzentration in der Luft signifikant reduzieren. Damit sinkt auch die Zahl der Krankenhausaufenthalte und Todesfälle aufgrund von Atemwegs-Erkrankungen. Die Ergebnisse sind jetzt in der Fachzeitschrift „Nature Communications, Earth & Environment“ erschienen.

Read More